ArticleACS biomaterials science & engineering2025
Reducing Complexity in Lipid Nanoparticles: Three-Component Zwitterionic Amino Lipids for Targeted Extrahepatic mRNA Delivery.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ionizable Cholesterol-Integrated Lipid Nanoparticles for Efficient siRNA Delivery to Solid Tumors.ChemMedChem · 2026Article
- Azobenzene-bridged ionizable amphiphilic Janus glycosides for light-controlled, single-component and organ-modulable pDNA delivery.Communications chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Simplicity and chemical expansion of lipid nanoparticles (LNPs) offer the potential for increased therapeutic benefit of mRNA vaccines and medicines. 3-Component Zwitterionic Amino Lipid (ZAL) LNPs offer simplicity and varied organ target scope, though there is a lack of chemical and formulation exploration with this class of lipids. Herein, we report the synthesis and evaluation of ZALs with improved biocompatibility, enhanced mRNA delivery efficacy, and extrahepatic organ-specific delivery through derivation at the secondary hydroxyl position with opivalate, chloride, bromide, and acetate. Evaluation of these novel ZAL molecules revealed organ-specific delivery trends, changes in delivery efficacy, and an engineering framework for chemically modifying lipid components that correlate with each specific chemical modification. Furthermore, the most efficacious ZAL derivative, which contains an acetate modification, displayed enhanced immune cell transfection in an organ-specific manner. This study provides a roadmap for reducing the complexity of LNPs by decreasing the number of lipid components in an LNP from the canonical 4 lipids to 3 lipids and expands the chemical scope of LNPs capable of mediating extrahepatic delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.